Main Article Content
Breast cancer (BC),- the most common cancer in women is considered. 1.5 million new cases are detected every year and this is 25% of all malignant tumors. The incidence is growing rapidly in European countries. Especially often this process develops against the background of dyshormonal processes, based on this, a retrospective analysis was carried out in order to identify the role of dyshormonal pathology in the development of precancerous diseases.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
"Modern strategy for the prevention of breast cancer." A.A. Meshcheryakov 2017
"Intraepithelial neoplasia of the mammary gland." Efremov G.D. 2013
"Pathomorphological and immunohistochemical studies of myoepithelium in hyperplastic processes and malignant neoplasms." Ivshina Yu.A. 2005
"Clinical and morphological features of polycentric growth and relapse in the treatment of colorectal cancer." S.V. Vtorushin 2012
"Clinical, morphological and molecular genetic features in the diagnosis and treatment of breast cancer." Kakharov A.Zh. 2019
Kogan I.Yu., Myasnikova M.O., Musina E.V. Progesterone in the treatment of mastopathy. Ed. E.K. Ailamazyan. SPb, 2012.68 p. (in Russian).
De Boever J., Verheugen C., Van Maele G., Vandekerckhove D. Steroid concentrations in serum, breast glandular tissue, and breast cyst fluid in control and progesterone-treated patients. Endocrinology of cystic breast disease. Ed. A. Angeli. New York: Raven Press, 1983. Rr. 93-9.
Du J.Y., Sanchez P., Kim L. et al. Percutaneous administration of progesterone by cream or gel in postmenopausal women: a randomized crossover study of serum, whole blood, saliva, and capillary blood progesterone levels. Menopause 2013 20 (11): 1169–75.
Zava D.T., Groves M.N., Stanchik F.Z. Percutaneous absorption of progesterone. Maturitas 2014, 77 (2): 91-2